In late 2022, Lilly Labs announced the launch of two groundbreaking weight loss drugs, Mounjaro and Zepbound, designed to transform obesity treatment. Two other drug companies have copied these drugs to sell for their own profit, and, in reaction, Lilly sued both.
Mounjaro, an injectable medication, targets appetite regulation and glucose metabolism, with clinical trials showing an average weight loss of 15-20% over 24 weeks. Its efficacy is enhanced when combined with a reduced-calorie diet and exercise.
Zepbound, an oral medication, complements Mounjaro by improving metabolic efficiency and reducing cravings. This leads to significant reductions in caloric intake.
In late March, Lilly Labs filed a lawsuit against companies Strive Pharmacy and Empower Pharmacy. The lawsuit alleges that these companies illegally copied their drugs for profit by making compounded or personalized drugs based on each patient. Lily began this because they believe that the drugs are not compounded, but instead are just a copy of Lilly’s medication with a few minor tweaks. These companies believe Lilly is overstepping regulations for their own profit and not allowing them to help their patients.